The Role of Salivary Pepsin in the Diagnosis of Gastroesophageal Reflux Disease (GERD) Evaluated Using High-Resolution Manometry and 24-Hour Multichannel Intraluminal Impedance-pH Monitoring

Background: The Lyon Consensus classification confirms or rules out gastroesophageal reflux disease (GERD). The refractory symptoms of patients with GERD taking proton pump inhibitors (PPIs) are challenging in clinical practice. Salivary pepsin concentration was proposed as a diagnostic biomarker for GERD. We aimed to determine the diagnostic value of salivary pepsin concentration for patients with conclusive GERD, based on the Lyon classification, and the correlation of salivary pepsin concentration with parameters of high-resolution manometry and 24-h multichannel intraluminal impedance-pH in patients with PPI-refractory symptoms.

Material/Methods: Saliva samples obtained from 130 patients who were suspicious for GERD and had PPI-refractory symptoms were used for pepsin determination using the enzyme-linked immunosorbent assay. All patients underwent upper gastrointestinal endoscopy, high-resolution manometry, 24-h multichannel intraluminal impedance, and pH recording and were classified as conclusive GERD, inconclusive GERD, and evidence against GERD groups according to Lyon classification.

Results: Salivary pepsin concentration was 8.2 ng/mL (3.8–17.8 ng/mL), 4.0 ng/mL (2.3–6.1 ng/mL), and 2.4 ng/mL (2.2–3.1 ng/mL) in conclusive GERD, inconclusive GERD, and evidence against GERD groups, respectively (P<0.001), and had a negative correlation with distal mean nocturnal baseline impedance and positive correlations with acid exposure time, total number of reflux events, and esophagogastric junction type. The area under the ROC curve of salivary pepsin for conclusive GERD was 0.76 (0.68–0.84), with a sensitivity of 76.36% and a specificity of 63.41% for conclusive GERD diagnosis at a cut-off value of 4.21 ng/mL.

Conclusions: Salivary pepsin test had moderate diagnostic value for conclusive GERD by Lyon classification in patients with PPI-refractory symptoms.

MeSH Keywords: Diagnosis • Esophageal pH Monitoring • Gastroesophageal Reflux • Pepsin A • Saliva

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/927381
Background

Gastroesophageal reflux disease (GERD) is a common esophageal disease with increasing prevalence worldwide [1,2]. It is defined by the Montreal Definition and Classification of GERD as a digestive disorder or complication caused by the reflux of the stomach contents into the esophagus [3]. The first-line treatment for GERD is a proton pump inhibitor (PPI). However, the symptoms of up to 40% of patients are not well controlled by PPIs [4]. When patients have persistent troublesome GERD symptoms and objective evidence of GERD after optimized PPI therapy, it is defined as PPI-refractory GERD, which is a challenging problem in clinical practice [5–7]. Although PPI-refractory GERD is a benign disease, like inflammatory bowel disease, it significantly decreases the quality of life of patients [8].

GERD is diagnosed based on esophageal tests including high-resolution manometry (HRM), esophagogastroduodenoscopy, and ambulatory reflux monitoring according to the practical procedure guidelines provided by the Lyon Consensus. In comparison with other guidelines for GERD, the Lyon Consensus clearly defines parameters that conclusively establish the presence of GERD and characteristics that rule out GERD. The presence of severe esophagitis, Barrett’s esophagus, peptic strictures, and acid exposure time (AET) >6% indicate conclusive evidence of GERD. The combination of normal endoscopy and distal AET <4% and reflux episodes <40 per 24 h off-PPI pH-impedance monitoring provides sufficient evidence refuting GERD. In addition, the Lyon Consensus includes novel parameters, such as the post-reflux swallow-induced peristaltic wave index (PSPWI), mean nocturnal baseline impedance (MNB), esophageal gastric junction (EGJ) type, and esophagogastro-esophageal junction contractile integral (length and vigor) (EGJ-CI) [9]. However, esophagogastroduodenoscopy, HRM, and ambulatory reflux monitoring are all invasive and relatively expensive procedures and are not considered ideal diagnostic tools.

Pepsin is a proteolytic enzyme whose precursor pepsinogen is produced only in the stomach. Therefore, an increased pepsin level in saliva is considered a specific biomarker for gastric reflux or laryngopharyngeal reflux [10–16]. Some studies have used the salivary pepsin level as a useful diagnostic marker for GERD [13–16]. Detecting salivary pepsin using the fibrinogen digestion method, western blot analysis, enzyme-linked immunosorbent assay (ELISA), and Peptest, a rapid lateral flow test, is considered to be convenient and noninvasive [13–17]. Wang et al. validated the efficacy of Peptest for the diagnosis of GERD in a multicenter study in China of 1032 patients with suspected gastroesophageal reflux, including 488 patients with non-erosive reflux disease (NERD), 221 patients with erosive esophagitis, and 323 healthy controls and found that Peptest had a specificity of 60% and a sensitivity of 85%, 86%, and 84% for GERD, NERD, and erosive esophagitis, respectively [18]. Hayat et al. used the salivary pepsin level determined by using Peptest to discriminate patients with reflux-related symptoms (58 patients with GERD and 26 patients with hypersensitive esophagus) from patients with functional heartburn (FH, n=27) and healthy controls (n=100) and found that Peptest showed a sensitivity of 78.6% and specificity of 64.9% in the diagnosis of GERD and hypersensitive esophagus [12].

However, no studies have explored the association of salivary pepsin concentration with GERD classification based on the Lyon Consensus in patients with PPI-resistant symptoms and the relationship of salivary pepsin concentration with MNBI, PSPW, EGJ type, and EGJ-CI. The present study aimed to (1) assess the diagnostic value of salivary pepsin concentration for conclusive GERD by the Lyon Consensus in patients with PPI-refractory symptoms and (2) explore the relationships of salivary pepsin concentration with GERD classification by the Lyon Consensus in patients with PPI-refractory symptoms, as well as with MNBI, PSPW, EGJ type, and EGJ-CI.

Material and Methods

Subjects

A total of 130 adult patients with PPI-refractory symptoms of suspicious GERD who were admitted to the Beijing Tongren Hospital were enrolled in the study. Patients who had at least a 2-week history of symptoms of heartburn with or without regurgitation were eligible for enrollment as patients suspicious for GERD. Those patients who did not respond to twice-daily PPI therapy for at least 8 weeks were diagnosed with PPI-refractory symptoms [4–6,19]. As HRM and impedance-pH/manometry are valuable tools in clinical and esophageal investigation [20], all patients underwent a salivary pepsin test, endoscopy, HRM and 24-h multichannel intraluminal impedance and pH recording (24-h MII-pH). Patients who had histories of thoracic, esophageal, or gastric surgery, eosinophilic or infectious esophagitis, and severe esophageal motility disorders, such as achalasia and scleroderma, or were pregnant were excluded. The study was approved by the Beijing Tongren Hospital Medical Ethics Committee (No. TRECKY2015-114). All participants signed the informed consent prior to participating in the study.

Saliva collection and pepsin assay

Salivary samples were collected when patients awoke (around 7 AM) and 2 h after breakfast (around 10 AM). Patients spit at least 2 mL of saliva into testing tubes containing 0.5 mL of 0.01 M citric acid (pH 2.5), which were then stored at –80°C before analysis. For pepsin measurement, salivary samples were centrifuged at 1000 g for 15 min at 4°C. The supernatants were
then collected and used to measure pepsin levels as described previously [21] using an ELISA kit (Cloud-Clone, Houston, TX, USA) with a minimum detectable level of <0.93 ng/mL.

**Endoscopic examination**

To assess mucosal injury, all patients underwent upper gastrointestinal endoscopy using a GIF-260 upper gastrointestinal endoscope (Olympus, Japan). Esophagitis was defined as macroscopically visible erosion within the distal esophagus during endoscopic examination and was graded according to the Los Angeles (LA) Classification [22].

**MII-pH recording**

All patients were instructed to stop treatment with PPIs, H2 receptor antagonists, and prokinetics at least 7 days prior to reflux monitoring. The position of the lower esophageal sphincter was measured using HRM, and MII-pH was recorded for at least 23 h after an overnight fast. The pH-impedance catheter with 8 impedance rings and 1 pH ring (Ref. No 261A, Given Imaging, Los Angeles, CA, USA) was placed in the nose to ensure that the distal esophageal pH sensor was 5 cm proximal to the lower esophageal sphincter (LES) and impedance sensors were positioned 3, 5, 7, 9, 15, and 17 cm above the LES. During data acquisition, patients recorded their meals and activities and logged their symptoms electronically. After 24 h, the patients returned to the hospital for catheter removal. At this time, the symptom diaries were reviewed. The total reflux events and total AET were recorded. The mean value of 3 measurements of 10 min taken during the nighttime recumbent period was calculated to obtain the MNBI. The mean value of the distal 4 channels was calculated as distal MNBI [23]. The PSPW was defined as previously described [24]. The PSPWI was calculated manually as the ratio of the number of PSPWs to the number of total reflux events [24]. Data from the pH-impedance monitor were downloaded from an ambulatory pH monitoring system (Ohmega, Medical Measurement Systems, Inc, Williston, VT, USA) and analyzed using the MMS database software v9.3 (Medical Measurement Systems). All data were initially identified by the software and subsequently verified and calculated by 2 of the authors (GZH and WYH) for accuracy confirmation.

**HRM recording**

HRM was performed after an overnight fast using a 22-channel transtracheal multilumen polyvinyl catheter (diameter, 3.6 mm; Medical Measurement Systems), which was perfused continuously with distilled water at a rate of 0.15 mL/min by a low-compliance pneumo-hydraulic capillary infusion system (Solar GI; Medical Measurement Systems). Esophageal motility was assessed by 10 water swallows (5 mL/swallow) at 30 s intervals in a recumbent position. HRM recordings were analyzed manually using database software v9.3 (Medical Measurement Systems). Manometry data were collected and analyzed according to the Los Angeles (LA) Classification v3.0 [25]. The EGI morphology was classified into 3 subtypes according to the relative localization of the LES and crural diaphragm as described in the Chicago Classification. EGI-CI was evaluated as previously described [26,27]. Fragmented peristalsis and ineffective esophageal motility were defined as hypomotility in our study.

**Group definitions**

Patients were classified into 3 groups on the basis of upper endoscopic findings, 24-h pH-MII monitoring, and HRM results based on the Lyon Consensus as follows: (1) conclusive evidence for GERD (conclusive GERD): presence of erosive esophagitis LA grade C&D, long-segment Barrett’s esophagus or peptic strictures and/or AET >6%; (2) evidence against pathologic reflux (evidence against GERD): without erosive esophagitis, AET <4%, and <40 reflux episodes while the patients were on PPIs; (3) inconclusive evidence for GERD (inconclusive GERD): LA grade A&B erosive esophagitis, and/or AET between 4% and 6%, and/or 40 to 80 reflux episodes. Factors such as positive reflux-symptom association, which was defined as the symptom index > 50%, the symptom association probability >95%, reflux episode >80, MNBI <2292 ohms, PSPWI <61%, hiatus hernia, esophageal hypomotility, or increased confidence for presence of pathological reflux when evidence was otherwise borderline or inconclusive [9,28].

**Statistical analysis**

Data were analyzed using SPSS v23.0 (SPSS Inc, Chicago, IL, USA) and Prism software v6.0 (GraphPad Software Inc, La Jolla, CA, USA). Categorical data were expressed as numbers or percentages. Normality of data was analyzed with the Shapiro-Wilk test [29]. Continuous data with a non-normal distribution were presented as median (interquartile range [IQR]). Continuous data with a normal distribution were presented as mean±standard deviation. Categorical variables were analyzed using Pearson’s chi-squared test, and continuous variables were analyzed using the Mann-Whitney U test with Bonferroni correction. One-way analysis of variance was used to compare continuous variables among groups. Spearman’s or Wilcoxon rank-sum tests were used to assess the correlations between pepsin concentration and reflux/HRM variables. To determine the diagnostic value of the salivary pepsin concentration of GERD, receiver operator characteristic (ROC) curves were constructed, which offered a summary of sensitivity and specificity across a range of cut-off points. By maximizing Youden’s index, the optimal cut-off point was obtained [30]. A value of $P<0.05$ was taken to indicate statistical significance.
Results

The demographic characteristics of patients and the results of endoscopy, 24-h pH-MII monitoring, and HRM

A total of 130 patients with refractory GERD symptoms were included. As shown in Figure 1, 48 patients had conclusive GERD, 58 patients had inconclusive GERD, and 24 patients had evidence against GERD based on the Lyon Consensus and the results of upper endoscopic findings and 24-h pH-MII monitoring. Of the 48 patients with conclusive GERD, 4 had LA grade C&D erosive esophagitis, 1 had long-segment Barrett’s mucosa, 1 had peptic strictures on endoscopy, and 44 had AET >6%. Of the 58 patients with inconclusive GERD, 42 had LA grade A&B erosive esophagitis, 24 had an AET between 4% and 6%, 22 had positive reflux-symptom association, 16 had reflux episode >80, 33 had low MNBI (<2292 ohms), and 58 had low PSPWI (PSPWI <61%). Of the 58 patients with inconclusive GERD, 10 had reflux hypersensitivity (RH), and 24 patients had normal distribution and the other parameters had a non-normal distribution (P<0.05).

Among patients with evidence against GERD, there were no significant differences between the RH and FH groups in age (53.2±14.2 years vs. 53.1±11.7 years; P=0.981), BMI (24.4±3.2 vs. 22.3±4.6; P=0.221), AET (1.5% [0.8–2.7%] vs. 0.7 [0–1.9%]; P=0.264), reflux events (31.0 [11.2–33.5] vs. 21.0 [18.0–27.3]; P=0.828), LES (19.6 mmHg [12.9–30.2 mmHg] vs. 31.9 mmHg [21.8–72.9 mmHg]; P=0.080), EGJ-CI (12.6 mmHg·cm [10.9–17.1 mmHg·cm] vs. 17.5 mmHg·cm [12.8–28.9 mmHg·cm]; P=0.103), and DCI (337.3 [274.3–918.0] vs. 518.5 [316.0–1328.8]; P=0.295). However, there were significant differences between the RH and FH groups in PSPWI (33.3% [29.5–44.2%] vs. 45.7% [37.5–48.9%]; P=0.014) and MNBI (2026.6±582.9 Ω vs. 2646.5 ± 591.6 Ω; P=0.018).

Salivary pepsin concentration

The salivary pepsin concentrations at waking and after breakfast are shown in the Table 1 and Figure 2A, 2B. The salivary pepsin concentrations at waking and after breakfast were not significantly different for the same patients (P=0.854); therefore, the higher value was used for further analysis and is listed in the Table 1. Overall, salivary pepsin concentrations were significantly different among patients with conclusive GERD, inconclusive GERD, and evidence against GERD (P<0.001) (Table 1, Figure 2C). Pepsin concentration was the highest at 8.2 ng/mL (3.8–17.8 ng/mL) for patients with conclusive GERD, followed in turn by 4.0 ng/mL (2.3–6.1 ng/mL) for patients with inconclusive GERD and 2.4 ng/mL (2.2–3.1 ng/mL) for patients with evidence against GERD. In addition, among patients with evidence against GERD, the salivary pepsin concentration was not significantly different between the RH and FH groups (2.3 ng/mL [2.1–8.8 ng/mL] vs. 2.4 ng/mL [2.2–3.0 ng/mL]; P=0.335).

The diagnostic value of salivary pepsin concentration was calculated using the ROC curve to differentiate patients with conclusive GERD from patients with inconclusive GERD (Figure 3). The AUC area of salivary pepsin concentration was 0.76 (0.68–0.84) for diagnosis of conclusive GERD. At the best cut-off salivary pepsin concentration of 4.21 ng/mL, its sensitivity and specificity were 76.36% and 63.41%, respectively.
|                              | Conclusive GERD (n=48) | Inconclusive GERD (n=58) | Against GERD (n=24) | P       | Pa       | Pb       | Pc       |
|------------------------------|------------------------|--------------------------|---------------------|---------|---------|---------|---------|
| Male gender, n (%)           | 25 (52.1)              | 17 (29.3)                | 8 (33.3)            | 0.048*  | 0.017*  | NS      | NS      |
| Age, Mean±SD                 | 58.8±13.4              | 57.5±12.2                | 53.1±12.5           | 0.203   | NS      | NS      | NS      |
| BMI, Mean±SD                 | 24.6±3.0               | 23.8±3.7                 | 23.2±4.2            | 0.235   | NS      | NS      | NS      |
| GERD-Q                       | 9.0 (7.0–11.0)         | 6.0 (6.0–11.0)           | 6.0 (6.0–9.0)       | 0.632   | NS      | NS      | NS      |
| Endoscopy                    |                        |                          |                     | 0.000*  | 0.032*  | <0.001* | <0.001* |
| Normal, n (%)                | 5 (10.4)               | 16 (27.6)                | 24 (100)            |         |         |         |         |
| LA-A&B, n (%)                | 38 (79.2)              | 42 (72.4)                | 0                   |         |         |         |         |
| LA-C&D&D&BE, n (%)           | 5 (10.4)               | 0 (0)                    | 0                   |         |         |         |         |
| 24 h pH-MII                  |                        |                          |                     |         |         |         |         |
| AET (%)                      | 1.0 (6.8–27.8)         | 1.0 (0.5–4.3)            | 1.0 (0.3–2.0)       | <0.001* | <0.001* | <0.001* | 0.013*  |
| DeMeester score              | 31.2 (23.8–87.9)       | 5.8 (1.8–13.3)           | 4.1 (1.5–6.9)       | <0.001* | <0.001* | <0.001* | 0.019*  |
| Distal MNBI (Ω)              | 1316.6±719.7           | 2246.9±596.5             | 2388.2±654.4        | <0.001* | <0.001* | <0.001* | 0.034*  |
| PSPWI (%)                    | 35.8 (13.9–30.6)       | 35.5 (23.2–36.7)         | 35.0 (33.1–46.8)    | <0.001* | <0.001* | <0.001* | <0.001* |
| Total reflux event (n)       | 44.5 (19–82.3)         | 55.0 (32.5–84.5)         | 22.5 (17.3–32.8)    | 0.002*  | NS      | <0.001* | <0.001* |
| At 17 cm above LES           | 2.5 (1.0–13.8)         | 9.0 (2.0–19.0)           | 5.0 (1.5–8.0)       | 0.017*  | NS      | NS      | 0.015*  |
| At 15 cm above LES           | 13.0 (2.0–24.8)        | 16.5 (4.8–35.3)          | 8.5 (5.0–14.0)      | 0.114   | NS      | NS      | 0.041*  |
| At 9 cm above LES            | 30.5 (6.3–57.0)        | 46.0 (22.8–73.3)         | 19.0 (12.5–27.8)    | 0.011*  | NS      | NS      | <0.001* |
| At 7 cm above LES            | 38.0 (9.8–74.8)        | 51.0 (30.0–79.3)         | 22.0 (17.0–31.0)    | 0.012*  | NS      | 0.031*  | <0.001* |
| At 5 cm above LES            | 44.5 (19–79.5)         | 55.9 (30.8–84.5)         | 22.5 (17.3–32.8)    | 0.008*  | NS      | 0.012*  | <0.001* |
| At 3 cm above LES            | 44.5 (19–82.3)         | 55.0 (32.5–84.5)         | 22.5 (17.3–32.8)    | 0.002*  | NS      | <0.001* | <0.001* |
| HRM                          |                        |                          |                     |         |         |         |         |
| LES pressure                 | 5.1 (1.4–9.8)          | 8.5 (4.7–11.9)           | 7.4 (4.1–11.5)      | 0.028*  | NS      | NS      | NS      |
| EGG type                     |                        |                          |                     | 0.031*  | 0.013*  | NS      | NS      |
| Type 1, n(%)                 | 4 (8.3)                | 12 (20.7)                | 6 (25)              |         |         |         |         |
| Type 2, n(%)                 | 29 (60.4)              | 40 (69.0)                | 15 (62.5)           |         |         |         |         |
| Type 3, n(%)                 | 15 (31.3)              | 6 (10.3)                 | 3 (12.5)            |         |         |         |         |
Correlation analyses were conducted to evaluate the potential correlations between salivary pepsin concentration, HRM, and 24-h pH-MII parameters. The results showed that salivary pepsin concentration was negatively correlated with distal MNBI ($r_s = -0.365$, $P < 0.001$) (Figure 4B) and positively correlated with AET ($r_s = 0.480$, $P = 0.001$), total number of reflux events ($r_s = 0.203$, $P = 0.02$), number of reflux events at 17 cm above LES ($r_s = 0.184$, $P = 0.036$), and EGJ type ($r_s = 0.268$, $P = 0.002$) (Figure 4A, 4C). However, salivary pepsin concentration had no significant correlation with sex ($P = 0.806$), age ($P = 0.262$), BMI ($P = 0.358$), GERD-Q ($P = 0.224$), number of reflux events at 15 cm above LES ($P = 0.076$), number of reflux events at 9 cm above LES ($P = 0.289$), number of reflux events at 7 cm above LES ($P = 0.066$), number of reflux events at 5 cm above LES ($P = 0.050$), PSPWI ($P = 0.06$), EGJ-CI ($P = 0.064$), LES pressure ($P = 0.310$), hypomotility ($P = 0.603$), and DCI ($P = 0.231$).

Table 1 continued. The demographic characteristics, endoscopy, 24-h pH-MII monitoring and HRM results of 130 patients with refractory GERD symptoms.

|                          | Conclusive GERD (n=48) | Inconclusive GERD (n=58) | Against GERD (n=24) | P    | Pa | Pb | Pc |
|--------------------------|------------------------|--------------------------|---------------------|------|----|----|----|
| EGJ-CI (mmHg·cm)         | 12.7 (8.5–22.8)        | 16.5 (9.3–22.9)          | 16.0 (11.2–24.7)    | 0.648 | NS | NS | NS |
| Normal motility, n (%)   | 14 (39.2)              | 26 (44.8)                | 16 (66.7)           | 0.522 | NS | NS | NS |
| DCI                      | 400.5 (192.5–668.0)    | 553.0 (306.8–849.0)      | 462.5 (280.8–1043.3)| 0.057 | 0.017* | 0.041* | NS |
| At waking                | 6.4 (2.7–11.3)         | 3.0 (2.2–7.4)            | 2.2 (1.3–2.4)       | 0.011* | 0.001* | 0.012* | NS |
| After meal               | 6.3 (3.2–12.7)         | 3.3 (2.3–6.1)            | 2.3 (2.2–3.0)       | 0.024* | NS | 0.003* | NS |
| The higher conc.         | 8.2 (3.8–17.8)         | 4.0 (2.3–6.1)            | 2.4 (2.2–3.1)       | 0.007* | 0.023* | 0.003* | NS |

Values are presented as median and interquartile range, except for age, BMI, EGJ-CI, MNBI, and PSPWI (mean and standard deviation); and male sex, Lyon classification, EGI type, and endoscopy (n and %). BMI – body mass index; GERD – gastroesophageal reflux disease; GERD-Q – gastroesophageal reflex disease questionnaire; BE – Barrett esophagus; AET – acid exposure time; MNBI – mean nocturnal baseline impedance; PSPWI – post-reflux swallow-induced peristaltic wave index; EGI – esophagogastric junction; EGI-CI – EGI contractile integral; DCI – distal contractile integral. Differences were significant when $P < 0.05$, and it is marked with * NS signifies not significant. P: ANOVA analysis of the three groups; $P_a$ – conclusive GERD vs. inconclusive GERD; $P_b$ – conclusive GERD vs. against GERD; $P_c$ – inconclusive GERD vs. against GERD.

Figure 2. (A) The concentrations of pepsin upon waking in different groups. (B) The concentrations of pepsin after breakfast in different groups. (C) The higher concentrations of pepsin for each patient (out of the 2 samples) in different groups. Abbreviation: GERD, gastroesophageal reflux disease.
Discussion

Pepsin is an enzyme activated from pepsinogen in the stomach. Therefore, its detection in saliva can be explained only by an episode of reflux. Salivary pepsin detection has been regarded as a noninvasive diagnostic method for GERD and laryngopharyngeal reflux (LPR). Du et al. showed that the AUC area was 0.868 for GERD. The patients with GERD in that study were defined as having reflux esophagitis (LA grades A to D), abnormal pH, or AET ≥4.2% [13]. In contrast, Race et al. found that salivary pepsin is not a reliable tool for the diagnosis of GERD [31]. A meta-analysis showed that the AUC area of salivary pepsin for LPR/GERD diagnosis was 0.71 (95% CI: 0.67–0.75), showing a moderate diagnostic value [32]. However, the patients with GERD in the previously published studies were not diagnosed according to the Lyon Consensus classification. The Lyon classification has strict standards for diagnosing or ruling out GERD. Only patients with high-grade esophagitis (LA grades C or D), peptic structuring, Barrett’s esophagus, or AET >6% were considered confirmatory evidence for GERD [9]. To the best of our knowledge, the salivary pepsin concentration in patients with PPI-refractory symptoms has not been previously measured, and ours is the first study showing that among suspicious GERD patients with PPI-refractory symptoms, patients with conclusive evidence of GERD had the highest salivary pepsin concentration in patients with refractory-PPI symptoms (P<0.001). The AUC area of salivary pepsin for conclusive GERD in patients with refractory-PPI symptoms was 0.76 (0.68–0.84), indicating a moderate diagnostic value.

Previous studies have shown that salivary pepsin concentration is positively correlated with AET and number of reflux episodes [12,13]. Likewise, our study showed positive correlations with the total number of reflux events ($r_s=0.203$, $P=0.02$) and AET ($r_s=0.480$, $P<0.001$). Theoretically, pepsin was brought to the oral cavity and pharynx by a reflux event; therefore, its concentration should be positively correlated with reflux burden, such as AET, number of reflux episodes, and number of proximal reflux episodes (number of reflux events 17 cm above LES), which is consistent with our present results and those of other researchers [12,13]. Also, theoretically, salivary pepsin should reflect only proximal reflux and is more likely to be negative for distal reflux. Therefore, salivary pepsin has a limited diagnostic accuracy for patients showing no proximal reflux. This might explain why the salivary pepsin test has only a moderate diagnostic value for conclusive GERD by the Lyon classification.

Figure 3. Receiver operating characteristic curve analysis for diagnostic value of salivary pepsin for conclusive gastro-esophageal reflux disease (GERD).

Figure 4. Correlation analyses between salivary pepsin concentration and (A) acid exposure time (AET); (B) mean nocturnal baseline impedance (MNBI); and (C) total reflux events.
classification for patients with PPI-refractory symptoms, since not all GERD patients have proximal reflux or LPR.

The Lyon Consensus proposes that >80 reflux episodes per 24 h are definitively abnormal, while a number <40 is physiological, and intermediate values are inconclusive [9]. In our study, the total reflux number was highest in the inconclusive GERD group (mostly non-acid and weakly acid reflux episodes), which might lead to a higher number of episodes of proximal reflux. Though the proximal and total reflux number was highest in the inconclusive GERD group, the pepsin concentration was highest in the conclusive GERD group. We thought the reason might be that the pepsin concentration in saliva was associated not only with the frequency but also with the duration of the reflux. It was unknown whether a long duration of reflux can bring more pepsin to saliva than a short duration of reflux, and this requires further study.

Du et al. showed that salivary pepsin concentration had a low negative correlation with LES pressure [13]. The PSPWI is a reflection of the integrity of primary peristalsis after reflux episodes [9,24]. The present study showed that salivary pepsin concentration had no significant correlation with PSPWI, EGJ-CI, LES pressure, hypomotility, and DCI, whereas it had a weak positive correlation with EGJ type, suggesting that salivary pepsin concentration is not correlated with esophageal motility, which is partially reflected by DCI and PSPWI. But salivary pepsin concentration was positively correlated with EGJ barrier function, which is partially reflected by EGJ type and LES pressure.

MNBI was measured by the average of baseline impedance from 24-h pH-MII monitoring during sleep over 3 periods of 10 min. MNBI reflects the integrity of mucosa and is associated with intercellular space and tight junctions. Previous studies showed that MNBI was the lowest for erosive esophagitis, followed by true NERD and then RH, and was normal in FH and healthy controls (≥2292 ohms) [33–35]. A low MNBI (<2292 Ω) might be a predictor of a good response to anti-reflux therapy [23]. It is interesting that salivary pepsin concentration was negatively correlated with distal MNBI. Several studies have shown that pepsin could directly damage the esophageal and laryngeal mucosa, subsequently resulting in inflammation. In non-acidic and weakly acidic reflux, pepsin might be a major cause of mucosa damage [36–38]. A study has shown that although laryngeal tissues can tolerate a pH of 4.0, in the presence of pepsin, laryngeal tissues will be damaged by that pH level [39]. The relationship of MNBI with pepsin concentration might indicate the pepsin could damage mucosal integrity.

Our study has several strengths. First, every patient with refractory symptoms of GERD underwent endoscopy, HRM, and 24-h MII-pH monitoring to rule out cancer, other causes of esophagitis, and severe esophageal motility disorders. Second, patients were accurately classified based on the Lyon Consensus. Third, our study is the first showing that salivary pepsin concentration was negatively correlated with MNBI, which indicates that pepsin might contribute to impaired mucosal integrity. Nevertheless, our study is the first to show the relationship of salivary pepsin concentration with the Lyon Consensus classification, as well as MNBI, PSPWI, and EGJ type in patients with PPI-refractory symptoms. Our study showed that among patients with PPI-refractory symptoms, salivary pepsin concentration was significantly higher in patients with conclusive GERD than in patients with inconclusive GERD and evidence against GERD. The elevated salivary pepsin concentration might support the diagnosis of conclusive GERD in patients with PPI-refractory symptoms. Also, our study is the first to demonstrate that salivary pepsin concentration had a negative correlation with distal MNBI and positive correlations with AET, total number of reflux events, number of proximal reflux episodes, and EGJ type.

However, our study also has some limitations. First, it was a single-center study and therefore may have selection bias. Second, some patients underwent endoscopy after PPI therapy, which may have led to a lower grade of endoscopic LA classification of patients in the initial disease period. Third, no follow-up data were obtained to assess the predictive value of salivary pepsin concentration for clinical outcomes. Finally, salivary pepsin concentration was not measured in duplicate during the ELISA procedure, which might hinder the pepsin measurement accuracy.

**Conclusions**

Overall, the salivary pepsin test had a moderate diagnostic value for conclusive GERD by the Lyon classification in patients with PPI-refractory symptoms.

**Conflict of interest**

None.
References:

1. Richter JE, Rubenstein IH: Presentation and epidemiology of gastroesopha-
gegal reflux disease. Gastroenterology, 2018; 154(2): 267–76

2. Eusebi LH, Ratnakumaran K, Yuan Y et al: Global prevalence of, and risk fac-
tors for, gastroesophageal reflux symptoms: A meta-analysis. Gut, 2018; 
67(3): 430–40

3. Vakil N, van Zanten SV, Kahrilas P et al: The Montreal definition and clas-
cification of gastroesophageal reflux disease: A global evidence-based con-
sensus. Am J Gastroenterol, 2006; 101(8): 1900–20; quiz 1943

4. Fass R, Sifrim D: Management of heartburn not responding to proton pump 
 inhibitors. Gut, 2009; 58: 295–309

5. Yadlapati R, DeLay K: Proton pump inhibitor-refractory gastroesophageal 
 reflux disease. Med Clin North Am, 2019; 103(1): 15–27

6. Yadlapati R, Vaezi MF, Vela MF et al: Management options for pa-
tients with GERD and persistent symptoms on proton pump inhibitors: 
Recommendations from an expert panel. Am J Gastroenterol, 2018; 113(7): 
980–86

7. Ates F, Francis DO, Vaezi MF: Refractory gastroesophageal reflux disease: 
Advances and treatment. Expert Rev Gastroenterol Hepatol, 2014; 8(6): 
657–67

8. Peery AF, Dellen ES, Lund J et al: Burden of gastrointestinal disease in the 
United States: 2012 update. Gastroenterology, 2012; 143(5): 1179–87

9. Gavali CP, Kahrilas PJ, Savarino E et al: Modern diagnosis of GERD: The 
Lyon Consensus. Gut, 2018; 67(7): 1351–62

10. Doğru M, Kuran G, Haytoğlu S et al: Role of laryngopharyngeal reflux in the 
pathogenesis of otitis media with effusion. J Int Adv Otol, 2015; 11(1): 
66–71

11. Iannella G, Di NG, Plateroti R et al: Investigation of pepsin in tears of chil-
dren with laryngopharyngeal reflux disease. Int J Pediatr Otorhinolaryngol, 
2015; 79(12): 2312–15

12. Hayat JO, Gabbieta-Somnez S, Yazaki E et al: Pepsin in saliva for the diag-
nosis of gastroesophageal reflux disease. Gut, 2015; 64(3): 373–80

13. Du X, Wang F, Hu Z et al: The Diagnostic value of pepsin detection in sa-
liva for gastro-esophageal reflux disease: A preliminary study from China. 
BMJ Gastroenterol, 2017; 17(1): 107

14. Potluri S, Friedenberg F, Parkman HP et al: Comparison of a salivary/spu-
tum pepsin assay with 24-hour esophageal pH monitoring for detection of 
gastric reflux into the proximal esophagus, oropharynx, and lung. Dig Dis 
Sci, 2003; 48(9): 1813–17

15. Kim TH, Lee KJ, Yeo M et al: Pepsin detection in the sputum/saliva for the 
diagnosis of gastroesophageal reflux disease in patients with clinically 
suspected atypical gastroesophageal reflux disease symptoms. Digestion, 
2008; 77(3–4): 201–6

16. Saritas Yukseki E, Hong SK et al: Rapid salivary pepsin test: Blinded assess-
ment of test performance in gastroesophageal reflux disease. Laryngoscope, 
2012; 122(6): 1312–16

17. Hayat JO, Yazaki E, Moore AT et al: Objective detection of esophagoga-
stric reflux in patients with hoarseness and endoscopic signs of laryn-
geal inflammation. J Clin Gastroenterol, 2014; 48(4): 318–27

18. Wang YF, Yang CQ, Chen YX et al: Validation in China of a non-invasive sal-
vary pepsin biomarker containing two unique human pepsin monoclonal 
bodies to diagnose gastroesophageal reflux disease. J Dig Dis, 2019; 
20(6): 278–87

19. Fock KM, Talley N, Goh KL et al: Asia-Pacific consensus on the manage-
ment of gastroesophageal reflux disease: An update focusing on refractory re-
flux disease and Barrett’s oesophagus. Gut, 2016; 65(9): 1402–15

20. Kahrilas PJ, Sifrim D: High-resolution manometry and impedance-pH/ 
manometry: Valuable tools in clinical and investigational esophagology. 
Gastroenterology, 2008; 135(3): 756–69

21. Jung AR, Kwon OE, Park JM et al: Association between pepsin in the saliva 
and the subjective symptoms in patients with laryngopharyngeal reflux. J 
Voice, 2019; 33(2): 150–54

22. Lundell LR, Dent J, Bennett JR et al: Endoscopic assessment of esophagitis: 
Clinical and functional correlates and further validation of the Los Angeles 
classification. Gut, 1999; 45: 172–80

23. Patel A, Wang D, Sainani N et al: Distal mean nocturnal basal impedance 
upon pH-impedance monitoring predicts reflux burden and symptomatic 
outcome in gastroesophageal reflux disease. Aliment Pharmacol Ther, 
2016; 44: 890–98

24. Frazonzi M, Manta R, Mirante VG et al: Esophageal chemical clearance is 
impaired in gastroesophageal reflux disease – A 24h impedance-pH mon-
toring assessment. Neurogastroenterol Motil, 2013; 25: 399–406

25. Kahrilas PJ, Redenooord AJ, Fox M et al: The Chicago classification of esop-
haegal motility disorders, v3.0. Neurogastroenterol Motil, 2015; 27: 
160–74

26. Rengarajan A, Bokhir A, Gor P et al: Esophago gastric junction and esopha-
geal body contraction metrics on high resolution manometry predict esoph-
agal acid burden. Neurogastroenterol Motil, 2018; 30(5): e13267

27. Gor P, Li Y, Munigala S et al: Interrogation of esophago gastric junction bar-
rier function using the esophagogastrectomy junctional contractile: An ob-
servational cohort study. Dis Esophagus, 2016; 29: 820–28

28. Matteo G, Brigida B, Vincenzo S et al: The Lyon Consensus: Does it differ 
from the previous ones? J Neurogastroenterol Motil, 2020; 26(3): 311–21

29. Henderson AR: Testing experimental data for univariate normality. Clin 
Chim Acta, 2006; 366(1–2): 112–29

30. Steyerberg EW, Harrell FE, Borsboom GI et al: Internal validation of predic-
tive models. J Clin Epidemiol, 2001; 54(8): 774–81

31. Race C, Chowdry J, Russell JM et al: Studies of salivary pepsin in patients 
with gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2019; 
49(9): 1173–80

32. Wang J, Zhao Y, Ren J et al: Pepsin in saliva as a diagnostic biomarker in la-
yngopharyngeal reflux: A meta-analysis. Eur Arch Otorhinolaryngol, 2018; 
275(3): 671–78

33. Ya Mei S, Yan G, Feng G: Role of esophageal mean nocturnal baseline im-
pedance and post-reflux swallow-induced peristaltic wave index in discrimi-
inating Chinese patients with heartburn. J Neurogastroenterol Motil, 2019; 
25(4): 515–20

34. De Bortoli N, Martinucci I, Savarino E et al: Association between baseline 
impedance values and response proton pump inhibitors in patients with 
heartburn. Clin Gastroenterol Hepatol, 2015; 13: 1082–88, e1

35. Frazonzi M, Savarino E, de Bortoli N et al: Analyses of the post-reflux swall-
ow-induced peristaltic wave index and nocturnal baseline impedance pa-
rameters increase the diagnostic yield of impedance-pH monitoring of pa-
tients with reflux disease. Clin Gastroenterol Hepatol, 2016; 14: 40–46

36. Johnston N, Yan JC, Hoekzema CR et al: Pepsin promotes proliferation of la-
yngal and pharyngeal epithelial cells. Laryngoscope, 2012; 122(6): 1317–25

37. Adhami T, Goldblum JR, Richter JE et al: The role of gastric and duodenal 
agents in laryngeal injury: An experimental canine model. Am J Gastroenterol, 
2004; 99(11): 2098–106

38. Hirschowitz BI: Pepsin and the esophagus. Yale J Biol Med, 1999; 72(2–3): 
133–43

39. Bulmer DM, Ali MS, Brownlee IA et al: Laryngeal mucosa: Its susceptibility 
to damage by acid and pepsin. Laryngoscope, 2010; 120(4): 774–82